979 research outputs found
PERENCANAAN ALAT GALI MUAT DAN ANGKUT PADA PRODUKSI BATUBARA 20.000.000 TON DI PT. BUMI MERAPI ENERGI
No full textPT. Bumi Merapi Energi berencana meningkatkan target produksi batubara yang awalnya 2.000.000 ton menjadi 20.000.000 ton sehingga diperlukan perencanaan jumlah alat gali-muat dan alat angkut yang digunakan. Penelitian ini bertujuan untuk merencanakan jumlah alat gali-muat dan angkut yang diperlukan pada peningkatan produksi. Penelitian ini dilakukan dengan mengevaluasi produktivitas aktual alat gali muat dan angkut. Selanjutnya dilakukan perhitungan untuk mengetahui jumlah alat yang diperlukan untuk mencapai target produksi 20.000.000 ton batubara. Data yang diperlukan adalah data perhitungan produktivitas, rencana produksi dan sekuen penambangan. Data tersebut diolah dengan Minescape dan Microsoft Excel. Evaluasi produktivitas alat gali muat Excavator Doosan DX 520 LCA sebesar 1.936.832,4 ton/tahun dan produktivitas alat angkut Dumptruck Hino FM 320 sebesar 1.919.862 ton/tahun. Setelah dilakukan perbaikan efisiensi kerja, maka produktivitas alat gali muat Excavator Doosan DX 520 LCA naik menjadi 2.018.671,2 ton/tahun dan produktivitas alat angkut Dumptruck Hino FM 320 naik menjadi 2.000.984,4 ton/tahun sehingga target produksi tahun 2019 telah tercapai. Berdasarkan hasil produktivitas alat gali muat dan alat angkut yang telah dilakukan evaluasi maka didapatkan bahwa untuk mencapai target produksi sebesar 20.000.000 ton diperlukan alat gali muat Excavator Doosan DX 520 LCA sebanyak 10 unit dan alat angkut Dumptruck Hino FM 320 sebanyak 30 unit
A biodiversity policy framework for Lebanon - by Hana Kasem Ibrahim
No full textThesis (M.S.E.S.)--American University of Beirut, Interfaculty Graduate Environmental Sciences Program (Environmental Policy Planning), 2004.;"Advisor:Dr. Hala Gali Muhtasib, Professor, Biology--Co-Advisor: Dr. Dima Jamali, Assistant Professor, Business--Bibliography: leaves 152-164.The purpose of this work is to formulate a coherent biodiversity policy framewor k for Lebanon. To achieve this purpose, two case studies on South Africa and Cos ta Rica were reviewed, a survey was conducted to determine different biodiversit y stakehold
Supplementary Appendix 1c of "Toward a geography of community health workers in Niger: a geospatial analysis"
No full textSupplementary Appendix 1c contains all input datasets at 100m resolution and 1000m resolution used in the research article "Toward a geography of community health workers in Niger: a geospatial analysis" by Nicholas P. Oliphant, Nicolas Ray, Khaled Bensaid, Adama Ouedraogo, Asma Yaroh Gali, Oumarou Habi, Ibrahim Maazou, Rocco Panciera, Maria Muñiz, Zeynabu Sy, Debra Jackson, and Tanya Doherty. Files are available under the Creative Commons Attribution 4.0 International License. Attribution for input datasets is provided in Supplementary Appendix 1 of "Toward a geography of community health workers in Niger: a geospatial analysis" by Oliphant and colleagues
Supplementary Appendix 1b of "Optimizing geographical accessibility to primary health care at community level in Niger: a geospatial analysis"
No full textSupplementary Appendix 1b contains Supplementary Appendices 2-6, Videos 1-2, and all output datasets at 100m resolution and 1000m resolution for the research article "Optimizing geographical accessibility to primary health care at community level in Niger: a geospatial analysis" by Nicholas P. Oliphant, Nicolas Ray, Khaled Bensaid, Adama Ouedraogo, Asma Yaroh Gali, Oumarou Habi, Ibrahim Maazou, Rocco Panciera, Maria Muñiz, Zeynabu Sy, Debra Jackson, and Tanya Doherty. Files are available under the Creative Commons Attribution 4.0 International License. Tab "Readme" in the file "Supplementary Appendix 1b - Metadata" contains a description of all datasets contained in Supplementary Appendix 1b
Ar istorija pasmerkta skaldyti, o gal atvirkščiai – gali suvienyti? Atminties vaidmuo formuojant tarptautinius santykius Vidurio Europoje
No full textPagrindinis tyrimo klausimas – ar istorija pasmerkta skaldyti, o gal atvirkščiai – gali suvienyti? Autorius teigia, kad, viena vertus, tiesos sąvokos atsisakymas istoriografijoje gali paskatinti istoriją traktuoti kaip selektyvių argumentų rezervuarą politinėse kovose. Šia prasme istorija visada skaldys. Kita vertus, tiesa gali būti pasiekta. Mokslininkai turi kelis būdus patikrinti, kiek toli nuo tiesos yra teiginys apie istoriją. Egzistuoja šešios pagrindinės tikrinimo taisyklės, kurios aptariamos straipsnyje. Nagrinėjama nacionalinio tapatumo samprata, kultūra, suvokiama kaip nacionalinio tapatumo pagrindas, ir regioninio bendradarbiavimo kontekstas.The main research question is whether history is doomed to divide or whether it may unite. The author argues that, on the one hand, the rejection of the concept of truth in historiography may lead to treating history as a reservoir of selective argument in political struggles. In this sense, history will always divide. However, on the other hand, truth may be achieved. Scholars have several ways to test how far from the truth is a statement concerning history. There are six basic rules to test it, which are discussed in the article. The concept of national identity, culture perceived as the backbone of national identity and the regional cooperation context are examined
Thymoquinone: Fifty years of success in the battle against cancer models
No full textThymoquinone (TQ), the main active constituent of black seed essential oil, exhibits promising effects against inflammatory diseases and cancer. TQ, modulates signaling pathways that are key to cancer progression, and enhances the anticancer potential of clinical drugs while reducing their toxic side effects. Considering that TQ was isolated 50 years ago, this review focuses on TQ's chemical and pharmacological properties and the latest advances in TQ analog design and nanoformulation. We discuss our current state of knowledge of TQ's adjuvant potential and in vivo antitumor activity and highlight its ability to modulate the hallmarks of cancer. © 2013 Elsevier Ltd. All rights reserved.Abusnina A, 2011, CELL SIGNAL, V23, P152, DOI 10.1016-j.cellsig.2010.08.015; Akhondian J, 2011, EPILEPSY RES, V93, P39, DOI 10.1016-j.eplepsyres.2010.10.010; Al-Ali Amein, 2008, J Ayub Med Coll Abbottabad, V20, P25; Alam S, 2012, INT J NANOMED, V7, P5705, DOI 10.2147-IJN.S35329; Al-Amri A. M., 2009, Shiraz E Medical Journal, V10, P107; Alenzi FQ, 2010, BRIT J BIOMED SCI, V67, P20; Alhosin M, 2012, INVEST NEW DRUG, V30, P1813, DOI 10.1007-s10637-011-9734-1; Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016-j.bcp.2009.12.015; Al-Johar D, 2008, PHYTOTHER RES, V22, P1311, DOI 10.1002-ptr.2487; Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193; Arafa ESA, 2011, MUTAT RES-FUND MOL M, V706, P28, DOI 10.1016-j.mrfmmm.2010.10.007; Badary OA, 2001, CANCER DETECT PREV, V25, P362; Badary OA, 1999, J ETHNOPHARMACOL, V67, P135, DOI 10.1016-S0378-8741(98)00242-6; Badary OA, 1999, EUR J CANCER PREV, V8, P435, DOI 10.1097-00008469-199910000-00009; Badary OA, 2000, TOXICOLOGY, V143, P219, DOI 10.1016-S0300-483X(99)00179-1; Badr G, 2011, PLOS ONE, V6, DOI 10.1371-journal.pone.0023741; Banerjee S, 2010, NUTR CANCER, V62, P938, DOI 10.1080-01635581.2010.509832; Banerjee S, 2010, PHARM RES-DORDR, V27, P1146, DOI 10.1007-s11095-010-0145-3; Banerjee S, 2009, CANCER RES, V69, P5575, DOI 10.1158-0008-5472.CAN-08-4235; Basarslan F, 2012, HUM EXP TOXICOL, V31, P726, DOI 10.1177-0960327111433185; Brewer J, 2006, BIOMED SCI INSTRUM, V42, P37; Chehl N, 2009, HPB, V11, P373, DOI 10.1111-j.1477-2574.2009.00059.x; CREMER D, 1987, J MED CHEM, V30, P1678, DOI 10.1021-jm00392a027; Daba MH, 1998, TOXICOL LETT, V95, P23, DOI 10.1016-S0378-4274(98)00012-5; Das S, 2012, PLOS ONE, V7, DOI 10.1371-journal.pone.0046641; Dergarabetian Eileen Manasse, 2013, Front Biosci (Elite Ed), V5, P706; Effenberger K, 2010, CHEM BIODIVERS, V7, P129, DOI 10.1002-cbdv.200900328; Effenberger-Neidnicht K, 2011, CHEMBIOCHEM, V12, P1237, DOI 10.1002-cbic.201000762; El-Dakhakhny M., 1963, PLANTA MED, V11, P465; El-Dakhakhny M, 2002, J ETHNOPHARMACOL, V81, P161, DOI 10.1016-S0378-8741(02)00051-X; El Gazzar MA, 2007, BBA-GEN SUBJECTS, V1770, P556, DOI 10.1016-j.bbagen.2007.01.002; El-Mahdy MA, 2005, INT J CANCER, V117, P409, DOI 10.1002-ijc.21205; El Mezayen R, 2006, IMMUNOL LETT, V106, P72, DOI 10.1016-j.imlet.2006.04.012; El-Najjar N, 2010, APOPTOSIS, V15, P183, DOI 10.1007-s10495-009-0421-z; El-Najjar Nahed, 2011, J Chem Biol, V4, P97, DOI 10.1007-s12154-010-0052-4; Farah Nourelhoda, 2005, V41, P211; Fouda AMM, 2008, BASIC CLIN PHARMACOL, V103, P109, DOI 10.1111-j.1742-7843.2008.00260.x; Gali-Muhtasib H, 2008, J CELL MOL MED, V12, P330, DOI 10.1111-j.1582-4934.2007.00095.x; Gali-Muhtasib H, 2006, INT J BIOCHEM CELL B, V38, P1249, DOI 10.1016-j.biocel.2005.10.009; Gali-Muhtasib H, 2008, CANCER RES, V68, P5609, DOI 10.1158-0008-5472.CAN-08-0884; Gali-Muhtasib H, 2004, INT J ONCOL, V25, P857; Gali-Muhtasib HU, 2004, ANTI-CANCER DRUG, V15, P389, DOI 10.1097-01.cad.0000125054.43188.56; Ganea GM, 2010, NANOTECHNOLOGY, V21, DOI 10.1088-0957-4484-21-28-285104; Gohari AR, 2012, SCI WORLD J, DOI 10.1100-2012-203861; Gokce A, 2011, HUM EXP TOXICOL, V30, P897, DOI 10.1177-0960327110382564; Grosso C, 2010, J SEP SCI, V33, P2211, DOI 10.1002-jssc.201000192; Gupta V.K., 2010, INT J RES PHARM SCI, V1, P163; Gurung R.L., 2010, PLOS ONE, V5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016-j.cell.2011.02.013; Harzallah HJ, 2012, OXID MED CELL LONGEV, DOI 10.1155-2012-854065; Hussain AR, 2011, FREE RADICAL BIO MED, V50, P978, DOI 10.1016-j.freeradbiomed.2010.12.034; Hussain J, 2010, NAT PROD COMMUN, V5, P1785; Ivankovic S., 2006, Experimental Oncology, V28, P220; Jafri SH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186-1756-9966-29-87; Kanter M, 2005, WORLD J GASTROENTERO, V11, P6662; Kanter M, 2008, NEUROCHEM RES, V33, P579, DOI 10.1007-s11064-007-9481-z; Kanter M, 2011, TOXICOL IND HEALTH, V27, P387, DOI 10.1177-0748233710387630; Kaseb AO, 2007, CANCER RES, V67, P7782, DOI 10.1158-0008-5472.CAN-07-1483; Koka PS, 2010, EXP BIOL MED, V235, P751, DOI 10.1258-ebm.2010.009369; Kolli-Bouhafs K, 2012, INVEST NEW DRUG, V30, P2121, DOI 10.1007-s10637-011-9777-3; Lei XF, 2012, DIGEST DIS SCI, V57, P2296, DOI 10.1007-s10620-012-2156-x; Li F, 2010, BRIT J PHARMACOL, V161, P541, DOI 10.1111-j.1476-5381.2010.00874.x; Lukas B, 2009, J AGR FOOD CHEM, V57, P1362, DOI 10.1021-jf802963h; Mansour MA, 2000, LIFE SCI, V66, P2583, DOI 10.1016-S0024-3205(00)00592-0; Manter DK, 2007, J CHEM ECOL, V33, P2133, DOI 10.1007-s10886-007-9368-0; Martin TM, 2006, BIOMED SCI INSTRUM, V42, P332; Mu Hai-qi, 2012, Zhonghua Yi Xue Za Zhi, V92, P392; Nagi MN, 2011, J BIOCHEM MOL TOXIC, V25, P135, DOI 10.1002-jbt.20369; Nagi MN, 2000, PHARMACOL RES, V41, P283, DOI 10.1006-phrs.1999.0585; Nagi MN, 2010, FOOD CHEM TOXICOL, V48, P2361, DOI 10.1016-j.fct.2010.05.072; Ng WK, 2011, TOXICOL IN VITRO, V25, P1392, DOI 10.1016-j.tiv.2011.04.030; Nili-Ahmadabadi A, 2011, DARU, V19, P282; Norwood AA, 2006, BIOMED SCI INSTRUM, V42, P350; Odeh F, 2012, DRUG DELIV, V19, P371, DOI 10.3109-10717544.2012.727500; Paramasivam A, 2012, TOXICOL LETT, V213, P151, DOI 10.1016-j.toxlet.2012.06.011; Pathan SA, 2011, BIOMED CHROMATOGR, V25, P613, DOI 10.1002-bmc.1492; Ravindran J, 2010, BIOCHEM PHARMACOL, V79, P1640, DOI 10.1016-j.bcp.2010.01.023; Reindl WG, 2008, CHEM BIOL, V15, P459, DOI 10.1016-j.chembiol.2008.03.013; Richards LR, 2007, BIOMED SCI INSTRUM, V43, P242; Roepke M, 2007, CANCER BIOL THER, V6, P160; Rooney S, 2005, ANTICANCER RES, V25, P4255; Ross Richards L, 2009, BIOMED SCI INSTRUM, V45, P268; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016-j.intimp.2005.06.008; Sayed-Ahmed MM, 2007, CLIN EXP PHARMACOL P, V34, P399, DOI 10.1111-j.1440-1681.2007.04560.x; Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158-1541-7786.MCR-07-2088; Shah M, 2010, INT J PHARMACEUT, V400, P165, DOI 10.1016-j.ijpharm.2010.08.008; Shah M, 2011, J NANOSCI NANOTECHNO, V11, P5702, DOI 10.1166-jnn.2011.4493; Singh A, 2013, COLLOID SURFACE B, V102, P822, DOI 10.1016-j.colsurfb.2012.08.038; Suddek GM, 2013, INFLAMMOPHARMACOLOGY, V21, P427, DOI 10.1007-s10787-012-0160-6; Sutton KM, 2012, BIOCHEM BIOPH RES CO, V426, P421, DOI 10.1016-j.bbrc.2012.08.111; Tan M, 2006, BIOMED SCI INSTRUM, V42, P363; Torres MP, 2010, MOL CANCER THER, V9, P1419, DOI 10.1158-1535-7163.MCT-10-0075; TRANG NTD, 1993, PLANTA MED, V59, P99, DOI 10.1055-s-2006-959619; Ulu R, 2012, FOOD CHEM TOXICOL, V50, P1675, DOI 10.1016-j.fct.2012.02.082; Velho-Pereira R, 2011, CELL BIOL INT, V35, P1025, DOI 10.1042-CBI20100701; Wang Yong-Mei, 2011, Zhonghua Yi Xue Za Zhi, V91, P3111; Wilson-Simpson F, 2007, BIOMED SCI INSTRUM, V43, P378; Woo CC, 2011, BIOCHEM PHARMACOL, V82, P464, DOI 10.1016-j.bcp.2011.05.030; Woo CC, 2012, BIOCHEM PHARMACOL, V83, P443, DOI 10.1016-j.bcp.2011.09.029; Worthen DR, 1998, ANTICANCER RES, V18, P1527; Wu Zhi-hao, 2011, Yaoxue Xuebao, V46, P910; Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158-1535-7163.MCT-08-0124; Yin Z, 2013, ACS CHEM BIOL, V8, P303, DOI 10.1021-cb3004379; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016-j.ajpath.2011.06.031; Zafeer MF, 2012, J BIOCHEM MOL TOXIC, V26, P199, DOI 10.1002-jbt.2140268
Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development
No full textDrugs derived from natural products, particularly from plants, are the leads of clinically used anticancer agents. Plant-derived anticancer agents in clinical use consist of the Vinca alkaloids, vinblastine and vincristine, camptothecin derivatives, paclitaxel, etoposide and teniposide, homoharringtonine and elliptinium. Extensive research has led to the identification of promising plant-derived anticancer agents in clinical development, namely flavopiridol, combretastatins and roscovitine. These compounds share common antitumor activities and signaling pathways targeting tumor cell cycle and cell death. This review presents the discovery of plant-derived anticancer agents, their biologic activities, with emphasis on cell cycle and apoptotic effects and combination strategies for treatment optimization. © 2007 Informa UK Ltd.Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074-jbc.M005267200; Advani Ranjana, 2006, J Natl Compr Canc Netw, V4, P241; Aggarwal BB, 2004, EXPERT OPIN INV DRUG, V13, P1327, DOI 10.1517-13543784.13.10.1327; Albihn A, 2006, J CELL BIOCHEM, V98, P1597, DOI 10.1002-jcb.20816; Alonso M, 2003, MOL CANCER THER, V2, P139; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182-blood-2004-07-2713; ARMSTRON.JG, 1967, CANCER RES, V27, P221; Atanasova G, 2005, BIOCHEM PHARMACOL, V70, P824, DOI 10.1016-j.bcp.2005.06.005; AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V259, P1, DOI 10.1016-0003-9861(87)90463-2; BAASKE DM, 1977, ANTIMICROB AGENTS CH, V12, P298; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074-jbc.M500806200; Baldwin E. L., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P363, DOI 10.2174-1568011054222364; Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016-j.lfs.2005.09.012; Bennouna J, 2005, EXPERT OPIN INV DRUG, V14, P1259, DOI 10.1517-13543784.14.10.1259; Bergeron S, 2004, MOL CANCER THER, V3, P1659; Bhutani Manisha, 2006, Indian J Chest Dis Allied Sci, V48, P49; Blagosklonny Mikhail V, 2002, Cell Cycle, V1, P375; Blagosklonny MV, 2005, CELL CYCLE, V4, P269; Blagosklonny MV, 2004, CELL CYCLE, V3, P1537, DOI 10.4161-cc.3.12.1278; Borgne A, 2006, ONCOGENE, V25, P7361, DOI 10.1038-sj.onc.1209718; BROOKS DJ, 1996, SEMIN ONCOL S, V23, pS30; Cai Z, 2001, LEUKEMIA, V15, P567; Cai Z, 2005, CHINESE MED J-PEKING, V118, P548; Carlson BA, 1996, CANCER RES, V56, P2973; CASTOR TP, 2006, MASS HIGH TECH, V22, P1; Ceruti S, 2006, J PHARMACOL EXP THER, V319, P1424, DOI 10.1124-jpet.106.109397; Chang BD, 1999, CANCER RES, V59, P3761; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016-S1074-5521(99)80048-9; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074-jbc.M102306200; Chiu CC, 2005, CANCER LETT, V223, P249, DOI 10.1016-j.canlet.2004.10.049; Ciusani E, 2005, J NEURO-ONCOL, V71, P19, DOI 10.1007-s11060-004-9180-4; Clardy J, 2004, NATURE, V432, P829, DOI 10.1038-nature03194; Clegg A, 2001, Health Technol Assess, V5, P1; Conroy T, 2002, CRIT REV ONCOL HEMAT, V42, P173, DOI 10.1016-S1040-8428(01)00180-9; Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016-j.jep.2005.05.011; Crescenzi E, 2005, CLIN CANCER RES, V11, P8158, DOI 10.1158-1078-0432; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016-S0140-6736(00)02074-2; Dark GG, 1997, CANCER RES, V57, P1829; Dasmahapatra G, 2006, MOL PHARMACOL, V69, P288, DOI 10.1124-mol.105.016154; Day TW, 2006, BIOCHEM PHARMACOL, V71, P1551, DOI 10.1016-j.bcp.2006.02.015; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158-0008-5472.CAN-04-0204; DENEKAMP J, 1982, BRIT J CANCER, V45, P136, DOI 10.1038-bjc.1982.16; Dickson M, 2004, NAT REV DRUG DISCOV, V3, P417, DOI 10.1038-nrd1382; Duflos Alain, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P55, DOI 10.2174-1568011023354452; Ehrlichova M, 2005, ANTICANCER RES, V25, P4215; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158-0008-5472.CAN-04-4095; Etievant C, 2001, CANCER CHEMOTH PHARM, V48, P62, DOI 10.1007-s002800100275; Fan MY, 2000, CANCER RES, V60, P6403; Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074-jbc.M411890200; FRESNO M, 1977, EUR J BIOCHEM, V72, P323, DOI 10.1111-j.1432-1033.1977.tb11256.x; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998; Fuchs C, 2006, CANCER TREAT REV, V32, P491, DOI 10.1016-j.ctrv.2006.07.001; Gali-Muhtasib H, 2002, CURR CANCER DRUG TAR, V2, P309, DOI 10.2174-1568009023333809; Garcia-Manero G, 2002, INTERNAL MED, V41, P254, DOI 10.2169-internalmedicine.41.254; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073-pnas.132275599; Giovannetti E, 2005, BRIT J CANCER, V92, P681, DOI 10.1038-sj.bjc.6602382; Glaberman Ursa, 2005, Expert Opin Drug Deliv, V2, P323, DOI 10.1517-17425247.2.2.323; Glaser T, 2001, BIOCHEM BIOPH RES CO, V281, P322, DOI 10.1006-bbrc.2001.4349; Gommersall LM, 2005, NAT CLIN PRACT ONCOL, V2, P298, DOI 10.1038-ncponc0196; GOODWIN S, 1959, J AM CHEM SOC, V81, P1903, DOI 10.1021-ja01517a031; Grant S, 2003, DRUG RESIST UPDATE, V6, P15, DOI 10.1016-S1368-7646(02)00141-3; Greenberg VL, 2005, ONCOGENE, V24, P4851, DOI 10.1038-sj.onc.1208624; Grivicich I, 2005, ONCOL RES, V15, P385; Groninger E, 2002, INT J ONCOL, V21, P1339; Hagg M, 2004, MOL CANCER THER, V3, P489; Hartmann JT, 2006, DRUG SAFETY, V29, P209, DOI 10.2165-00002018-200629030-00005; Hartwell JL, 1982, PLANTS USED CANC; Hassan MAIA, 2006, CANCER GENE THER, V13, P1105, DOI 10.1038-sj.cgt.7700984; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038-sj-onc.1206409; Henfling MER, 2004, INT J ONCOL, V25, P1437; Henley D, 2007, CANCER CHEMOTH PHARM, V59, P235, DOI 10.1007-s00280-006-0262-1; Holwell SE, 2001, BRIT J CANCER, V84, P290, DOI 10.1054-bjoc.2000.1587; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; HUANG MT, 1975, MOL PHARMACOL, V11, P511; Islaih M, 2005, MUTAT RES-FUND MOL M, V578, P100, DOI 10.1016-j.mrfmmm.2005.04.012; Iyer S, 1998, CANCER RES, V58, P4510; Jean-Decoster C, 1999, ANTI-CANCER DRUG, V10, P537, DOI 10.1097-00001813-199907000-00005; Jin J, 2006, LEUKEMIA, V20, P1361, DOI 10.1038-sj.leu.2404287; JOHNSON IS, 1963, CANCER RES, V23, P1390; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174-1568011023354290; Kanthou C, 2004, AM J PATHOL, V165, P1401, DOI 10.1016-S0002-9440(10)63398-6; Karp JE, 2005, CLIN CANCER RES, V11, P8403, DOI 10.1158-1078-0432.CCR-05-1201; Karpinich NO, 2006, J CELL PHYSIOL, V208, P55, DOI 10.1002-jcp.20638; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093-jnci-84.22.1736; Kawakami K, 1999, ANTICANCER RES, V19, P3927; Kelland Lloyd R, 2005, Expert Opin Emerg Drugs, V10, P413, DOI 10.1517-14728214.10.2.413; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021-jm00105a017; Kitada S, 2000, BLOOD, V96, P393; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038-nrd1657; Koizumi N, 2005, INT J ONCOL, V26, P1301; Kolfschoten GM, 2002, BIOCHEM PHARMACOL, V63, P733, DOI 10.1016-S0006-2952(01)00895-4; Kramer R, 2004, NAT REV DRUG DISCOV, V3, P965, DOI 10.1038-nrd1552; Kruczynski A, 1998, CANCER CHEMOTH PHARM, V41, P437, DOI 10.1007-s002800050764; Kumar L, 2006, NATL MED J INDIA, V19, P80; Kuo PL, 2005, CANCER LETT, V223, P293, DOI 10.1016-j.canlet.2004.09.046; Kuo PL, 2005, ANTI-CANCER DRUG, V16, P789, DOI 10.1097-01.cad.0000171768.36317.93; Kurosu T, 2005, APOPTOSIS, V10, P1111, DOI 10.1007-s10495-005-3372-z; LAVELLE F, 1995, SEMIN ONCOL S4, V22, pS3; Lee YK, 2006, MOL CANCER THER, V5, P138, DOI 10.1158-1535-7163.MCT-05-0235; Li QY, 2006, CURR MED CHEM, V13, P2021, DOI 10.2174-092986706777585004; Litz J, 2003, CLIN CANCER RES, V9, P4586; Liu XM, 2001, BRIT J CANCER, V85, P1403, DOI 10.1054-bjoc.2001.2107; Lobert S, 1998, MOL PHARMACOL, V53, P908; LOGH BH, 1994, CANC CHEMOTHER PHA S, V34, pS26; Lu KH, 2005, CLIN CHIM ACTA, V357, P65, DOI 10.1016-j.cccn.2005.02.003; Lu KH, 2005, J ORTHOP RES, V23, P988, DOI 10.1016-j.orthres.2005.01.018; Luo Chang Ying, 2004, Hematology, V9, P259, DOI 10.1080-10245330410001714194; Lyseng-Williamson KA, 2005, DRUGS, V65, P2513, DOI 10.2165-00003495-200565170-00007; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158-0008-5472.CAN-05-0233; Magalska A, 2006, INT J CANCER, V119, P1811, DOI 10.1002-ijc.22055; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021-ar0201198; Mialon A, 2005, MOL CELL BIOL, V25, P5040, DOI 10.1128-MCB.25.12.5040-5051.2005; Minderman H, 2005, MOL CANCER THER, V4, P885, DOI 10.1158-1535-7163.MCT-04-0048; Miyashita K, 2006, INT J MOL MED, V18, P249; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Navakauskiene R, 2004, ANN NY ACAD SCI, V1030, P393, DOI 10.1196-annals.1329.049; NEGORO S, 1991, J NATL CANCER I, V83, P1164, DOI 10.1093-jnci-83.16.1164; Newcomb EW, 2004, ANTI-CANCER DRUG, V15, P411, DOI 10.1097-01.cad.0000127332.06439.47; Newman DJ, 2002, CURR CANCER DRUG TAR, V2, P279, DOI 10.2174-1568009023333791; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021-np030096l; Ngan VK, 2000, CANCER RES, V60, P5045; NOBLE RL, 1958, ANN NY ACAD SCI, V76, P882, DOI 10.1111-j.1749-6632.1958.tb54906.x; Oberlies NH, 2004, J NAT PROD, V67, P129, DOI 10.1021-np030498t; O'Brien S, 2003, CANCER, V98, P888, DOI 10.1002-cncr.11620; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038-sj-cdd-4401012; OHASHI M, 1995, JPN J CANCER RES, V86, P819; Panno ML, 2006, FEBS LETT, V580, P2371, DOI 10.1016-j.febslet.2006.03.055; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074-jbc.M406543200; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038-sj.onc.1206777; Pepper Chris, 2003, Cell Cycle, V2, P53; Perez-Stable C, 2006, CANCER LETT, V231, P49, DOI 10.1016-j.canlet.2005.01.018; Pettit GR, 1982, CAN J CHEM, V60, P1347; PETTIT GR, 1987, CAN J CHEM, V65, P2390; PETTIT GR, 1995, ANTI-CANCER DRUG DES, V10, P299; Podwyssotzki V, 1881, PHARM J T, V12, P217; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038-nrc1977; POTIER P, 1989, SEMIN ONCOL, V16, P2; Pourroy B, 2004, MOL PHARMACOL, V66, P580; POWELL RG, 1972, J PHARM SCI, V61, P1227, DOI 10.1002-jps.2600610812; Pratt MAC, 2006, APOPTOSIS, V11, P589, DOI 10.1007-s10495-006-4603-7; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128-MCB.20.8.2629-2634.2000; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182-blood-2005-01-0320; Ramnath N, 2005, CANCER CHEMOTH PHARM, V56, P447, DOI 10.1007-s00280-004-0951-6; Reck M, 2006, LUNG CANCER, V53, P67, DOI 10.1016-j.lungcan.2006.04.001; Reichert JM, 2003, NAT REV DRUG DISCOV, V2, P695, DOI 10.1038-nrd1178; RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093-jnci-83.4.288; Rodriguez-Hernandez A, 2006, APOPTOSIS, V11, P131, DOI 10.1007-s10495-005-3276-y; Rossi A, 2003, ANTICANCER RES, V23, P1657; Rossi R, 2006, CANCER RES, V66, P1675, DOI 10.1158-0008-5472.CAN-05-2741; Russo AJ, 2006, CANCER RES, V66, P7253, DOI 10.1158-0008-5472.CAN-05-3725; Sambol EB, 2006, CANCER RES, V66, P5858, DOI 10.1158-0008-5472.CAN-05-2933; Savio M, 2006, CELL CYCLE, V5, P2153, DOI 10.4161-cc.5.18.3235; Scagliotti G, 2004, LUNG CANCER-J IASLC, V46, pS13, DOI 10.1016-S0169-5002(04)80037-0; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016-S1040-8428(00)00124-4; SENDEROWICZ AM, 2002, ONCOLOGIST S, V7, pS12; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038-sj.onc.1206954; Shapiro GI, 1999, CLIN CANCER RES, V5, P2925; SINGH MP, 1994, BIOCHEMISTRY-US, V33, P10271, DOI 10.1021-bi00200a007; Smith LM, 2005, CLIN CANCER RES, V11, P8449, DOI 10.1158-1078-0432.CCR-05-1224; Stiborova Marie, 2006, Biomedical Papers (Olomouc), V150, P13; Stiborova M, 2004, CANCER RES, V64, P8374, DOI 10.1158-0008-5472.CAN-04-2202; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158-0008-5472.CAN-05-1997; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016-S0014-2999(97)01520-3; Swanton C, 2006, CELL CYCLE, V5, P818, DOI 10.4161-cc.5.8.2682; Takahashi T, 2005, MOL CANCER THER, V4, P1039, DOI 10.1158-1535-7163.MCT-04-0282; Tang RP, 2006, MOL CANCER THER, V5, P723, DOI 10.1158-1535-7163.MCT-05-0164; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158-0008-5472.CAN-03-2770; Taniguchi T, 2005, INT J MOL MED, V15, P667; Tirado OM, 2005, CANCER RES, V65, P9320, DOI 10.1158-0008-5472.CAN-05-1276; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038-nrc1628; Tron GC, 2006, J MED CHEM, V49, P3033, DOI 10.1021-jm0512903; Venkataraman G, 2006, LEUKEMIA RES, V30, P1377, DOI 10.1016-j.leukres.2006.03.004; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021-ja00968a057; Wall NR, 1999, LEUKEMIA RES, V23, P881, DOI 10.1016-S0145-2126(99)00108-3; Wall NR, 2003, CANCER RES, V63, P230; Wang Q, 2004, ONCOGENE, V23, P426, DOI 10.1038-sj.onc.1207040; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074-jbc.274.12.8208; Wang Z, 2005, ANTICANCER RES, V25, P2367; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021-ja00738a045; Wehbe H, 2005, ANTICANCER RES, V25, P3865; Wesierska-Gadek J, 2005, MOL CANCER THER, V4, P113; West CML, 2004, ANTI-CANCER DRUG, V15, P179, DOI 10.1097-01.CAD.0000119456.84063.82; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158-0008-5472.CAN-03-0110; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016-0006-2952(93)90590-S; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158-1535-7163.MCT-06-0077; Xie WZ, 2006, AM J CHINESE MED, V34, P233, DOI 10.1142-S0192415X06003795; XU B, 1981, AM J CHINESE MED, V9, P268, DOI 10.1142-S0192415X81000354; Yinjun Lou, 2004, Am J Hematol, V76, P199, DOI 10.1002-ajh.20100; You YJ, 2005, CURR PHARM DESIGN, V11, P1695, DOI 10.2174-1381612053764724; Young SL, 2004, EXPERT OPIN INV DRUG, V13, P1171, DOI 10.1517-13543784.13.9.1171; Yu CR, 2003, CANCER RES, V63, P1822; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038-sj.onc.1209202; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174-1568009033333754; Zeng S, 2000, CLIN CANCER RES, V6, P3766; Zhao J, 2006, CANCER GENE THER, V13, P420, DOI 10.1038-sj.cgt.7700910; Zhao JS, 2005, INT J ONCOL, V27, P24756
Majlis Daerah Raub Pahang / Nor Shahira Ibrahim
No full textRaub is one of the tourism town of Pahang Darul Makmur. The Raub District is also a parliamentary constituency in Pahang, Malaysia. The town is situated 110 km from the Malaysian capital of Kuala Lumpur and 265 km from Pahang's capital, Kuantan. Raub is one of the oldest towns in Pahang. Raub district consists of 7 mukim (sub-districts), namely Batu Talam, Sega, Semantan Ulu, Dong, Ulu Dong, Gali and Tras. With an area of 2,271 km2, Raub district is situated in west of Pahang and between two range, Titiwangsa Range and Benom Mountain Range. Raub experiences a temperature range between 20 and 30 °C[1] annually and an average rainfall about 200 mm[citation needed], and is home to Fraser's Hill.The natural beauty of Raub town is an attraction to tourists from within country and overseas. Raub district Council was established through Pahang Darul Makmur government gazette on 4 June 1981 Jilid 34/12, No Gn 339, No Town.Pw 1236 effective on 1 July 1981. It has an area oOf 110.31 kilometres sq. Due to this total council area has been increased to 977.207 kilometres sq. Raub District Council area Raub has been broadened by taking Bukit Fraser area and other area in Raub district except forest reserve area effective on 7 November 1997 through Pahang Darul makmur Government gazette dated 31 December 1998,Jilid 51/27, No GN 1082, Plan No.PW. 3270. Besides that, some changes had been made towards Raub District Council organization where before this operation is placed under departments. Raub is administered by Raub District Council, with Dato' Haji Ismail bin Haji Mhd Ali being the Yang DiPertua. Raub has its own constituency in the Dewan Rakyat of the Malaysian Parliament. The incumbent MP is Ariff Sabri Abdul Aziz of the DAP. In turn, Raub delivers three seats to the Pahang State Legislative Assembly, comprising Batu Talam, Tras and Dong. Raub is the only place in western Pahang (Raub, Bentong and Kuala Lipis) that has state and federal-level administrative offices. There is a landmark building, situated next to Taman Bukit Koman (not to be confused with Kampung Bukit Koman), which contains most of the administrative offices, called Bangunan Gunasama Persekutuan. Inside Bangunan Gunasama Persekutuan, there are District Immigration Department, National Registry Department (District Branch) Office and other important offices in that building also. Besides that, there is Land Office which is on top of a hill, beside Taman Shahbandar, provides opportunity to renew their land title and land grant, unlike Bentong, they need to come to Raub to renew their land title. Actually, the existence of those administrative offices has its roots. During the early 20th century, because of massive gold mining activity, Raub was quickly developed and at once, it was tipped as the future administrative state capital for Pahang. However, at the last minute, Residence of Pahang decided to shift state administrative capital to Kuantan and left out Raub. Although Raub did not become state capital, however, British left a lot of administrative buildings in Raub, including the Resident's official residence (the present Raub District Officer's official residence) was situated in Raub
Radiosensitization of EMT6 mammary carcinoma cells by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide
No full textBackground and purpose: Previously, we have reported that 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide (DCQ) is a radiosensitizer. Here, we investigate the mechanism of radiosensitization. Materials and methods: EMT6 cells were treated with DCQ for 4 h prior to ionizing radiation (IR). Flow cytometry, clonogenic assay, TUNEL, and Western blotting were performed to assess the effect of treatment on cells. Results: Propidium iodide staining of EMT6 cells treated with IR ± DCQ revealed high numbers of cells with decreased DNA, consistent with an apoptotic response. TUNEL assay revealed apoptosis was 4percent, 38percent, and 49percent 24 h after treatment with IR alone, DCQ alone, and DCQ + IR, respectively. Clonogenic assays revealed that the survival of irradiated EMT6 cells was significantly reduced by DCQ treatment. DCQ treatment abrogated the radiation-induced expression of p21 and p53. The increased apoptosis observed in DCQ + IR-treated cells was correlated to suppression of radiation-induced phosphorylation of Akt and the expression of Bcl-XL. DCQ also caused the phosphorylation of mitogen-activated protein kinases Erk and Jnk. Conclusions: The radiosensitization effect of DCQ occurs through enhancement of radiation-induced apoptosis, which correlates to the inhibition of p-Akt kinase and Bcl-XL and the activation of Erk and Jnk kinases, but appears independent of p53 induction or modulation of Bax-Bcl-2 gene expression. These data suggest DCQ should be tested as a radiosensitizer in vivo and has potential in the treatment of human solid tumors. © 2008.Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126-science.281.5381.1322; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073-pnas.96.3.1002; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126-science.296.5573.1655; Chiosis G, 2001, BIOORG MED CHEM LETT, V11, P909, DOI 10.1016-S0960-894X(01)00099-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038-nrc883; Dangi S, 2003, CELL SIGNAL, V15, P667, DOI 10.1016-S0898-6568(03)00002-0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101-gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042-0264-6021:3510095; DIABASSAF M, 2000, MOL CARCINOG, V33, P198; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126-science.281.5381.1317; Figueroa C, 2003, J BIOL CHEM, V278, P47922, DOI 10.1074-jbc.M307357200; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016-S0167-4889(00)00018-5; Gali-Muhtasib H, 2004, INT J ONCOL, V24, P1121; Gali-Muhtasib HU, 2005, CANCER CHEMOTH PHARM, V55, P369, DOI 10.1007-s00280-004-0907-x; Gali-Muhtasib HU, 2001, ONCOL REP, V8, P679; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038-sj-onc-1205181; Gottschalk AR, 2005, INT J RADIAT ONCOL, V63, P1221, DOI 10.1016-j.ijrobp.2005.08.014; Gupta AK, 2001, CANCER RES, V61, P4278; HADDADIN MJ, 1993, HETEROCYCLES, V35, P1503; Harakeh S, 2004, CHEM-BIOL INTERACT, V148, P101, DOI 10.1016-j.cbi.2004.05.002; Itani W., 2007, RAD ONCOL, V2; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128-MCB.22.22.7831-7841.2002; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016-S0896-6273(02)00821-8; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126-science.275.5303.1132; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038-sj.onc.1204942; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016-S0092-8674(00)81871-1; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174-1568026023393318; Liang K, 2003, MOL CANCER THER, V2, P1113; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038-35003670; Lu Yiling, 2003, Rev Clin Exp Hematol, V7, P205; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038-sj.onc.1201585; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038-sj.onc.1203597; McKenna WG, 2003, ONCOGENE, V22, P5866, DOI 10.1038-sj.onc.1206699; Nakamura JL, 2005, J NEURO-ONCOL, V71, P215, DOI 10.1007-s11060-004-1718-y; POWIS G, 1994, CANCER RES, V54, P2419; Price BD, 1996, CANCER RES, V56, P246; Riesterer O, 2004, INT J RADIAT ONCOL, V58, P361, DOI 10.1016-j.ijrobp.2003.09.050; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038-5042; Shonai T, 2002, CELL DEATH DIFFER, V9, P963, DOI 10.1038-sj.cdd.4401050; Soderlund K, 2005, INT J ONCOL, V26, P25; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074-jbc.M111598200; Tenzer A, 2001, CANCER RES, V61, P8203; Watanabe H, 2004, INT J RADIAT BIOL, V80, P451, DOI 10.1080-09553000410001702355; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016-S1368-7646(02)00120-6; Yang J, 2003, MUTAT RES-REV MUTAT, V543, P31, DOI 10.1016-S1383-5742(02)00069-8; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126-science.7701324; Zhan M, 2004, HISTOL HISTOPATHOL, V19, P915; Zhang L, 2003, CANCER RES, V63, P422569
UJI BAKTERIOLOGIS AIR SUMUR GALI DITINJAU DARI FAKTOR KONSTRUKSI DAN SANITASI LINGKUNGAN SEKITAR SUMUR DI KELURAHAN MAKAWIDEY KECAMATAN AERTEMBAGA KOTA BITUNG
No full textSumur gali menyediakan air yang berasal dari lapisan tanah yang relatif dekat dari permukaan tanah sehingga dapat dengan mudah terkena kontaminasi melalui rembesan. Adapun tujuan penelitian ini yaitu untuk mengetahui kondisi bakteriologis air sumur gali ditinjau dari faktor konstruksi dan sanitasi lingkungan sekitar sumur di kelurahan Makawidey Kecamatan Aertembaga. Penelitian ini merupakan penelitian observasional dengan desain deskriptif berbasis laboratorium serta dilakukan pengamatan dan pengukuran menggunakan lembar checklist dan meteran. Uji kualitas bakteriologis air sumur gali dilakukan di laboratorium dengan parameter Total Coliform, sesuai persyaratan Peraturan Menteri Kesehatan nomor 32 tahun 2017. Hasil penelitian yang diperoleh yaitu semua sumur gali di kelurahan Makawidey tidak memenuhi syarat kontruksi dan sanitasi lingkungan sekitar sumur. Hasil uji laboratorium, menunjukkan bahwa dari terdapat 12 sumur yang tidak memenuhi syarat Total Coliform dan hanya 4 sumur yang memenuhi syarat. Kesimpulan penelitian ini yaitu 12 dari 16 sumur gali (75%) tidak memenuhi syarat total coliform dan 4 sumur (25%) memenuhi syarat. Secara keseluruhan (100%) sumur tidak memenuhi syarat konstruksi dan sanitasi. Saran dari penulis yaitu sebaiknya dilakukan perbaikan terhadap konstruksi sumur serta melakukan penambahan kaporit untuk meminimalisir jumlah bakteri coliform.Kata Kunci : Total Coliform Air Sumur Gali, Konstruksi Sumur, Sanitasi Lingkungan Sekitar SumurABSTRACTDug wells provide water from soil layers that are relatively close to the soil surface so that it can be easily exposed to contamination through seepage. The aim of this study is to determine the bacteriological conditions of dug well water in terms of construction factors and environmental sanitation around the well in the Makawidey sub-district of Aertembaga Subdistrict. This research was an observational study with a laboratory-based descriptive design and observations and measurements using a checklist and meter. Bacteriological quality test of dug well water was carried out in a laboratory with Total Coliform parameters, according to the requirements of Minister of Health Regulation number 32 of 2017. The results of this research is the construction and environmental sanitation of all dug wells in Makawidey were not eligible. Laboratory test results shows that there are 12 wells that not eligible due to the number of Total Coliform and only 4 wells that qualify. The conclusion of this research is that 12 of 16 wells (75%) not eligible according to the requirements of total coliform and 4 wells (25%) were eligible the requirements. Overall (100%) wells not eligible for construction and sanitation requirements. The suggestion from the author is that it’s better to improve the construction of wells and to add chlorine to minimize the number of coliform bacteria.Keywords: Total ColiformDigging WellWater, Well Construction, Environmental Sanitation Around Well
- …
